TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04101435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimFlu-S (QIS)
Description: This was an open study to demonstrate the use of AdimFlu-S (QIS) (2016-2017 season) vaccine in young subjects aged between 3 years old to 17 years old. All subjects were divided into two subgroups. That were subjects aged 3 to 8 years old, who received 2 doses of 0.5 mL vaccine separated by 4 weeks, and subjects aged 9 to 17 years old, who received one dose of 0.5 mL vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AdimFlu-S (QIS)
Description: This was an open study to demonstrate the use of AdimFlu-S (QIS) (2016-2017 season) vaccine in young subjects aged between 3 years old to 17 years old. All subjects were divided into two subgroups. That were subjects aged 3 to 8 years old, who received 2 doses of 0.5 mL vaccine separated by 4 weeks, and subjects aged 9 to 17 years old, who received one dose of 0.5 mL vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdimFlu-S (QIS)
Description: This was an open study to demonstrate the use of AdimFlu-S (QIS) (2016-2017 season) vaccine in young subjects aged between 3 years old to 17 years old. All subjects were divided into two subgroups. That were subjects aged 3 to 8 years old, who received 2 doses of 0.5 mL vaccine separated by 4 weeks, and subjects aged 9 to 17 years old, who received one dose of 0.5 mL vaccine.
Study: NCT01310218

Intervention type: OTHER
Group type: OTHER
Intervention: extended postoperative dressing
Description: 2 weeks of bulky dressing

Intervention type: OTHER
Group type: OTHER
Intervention: short postoperative dressing
Description: 2 days bulky dressing followed by bandaid
Study: NCT02447458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126
Description: MLN3126 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126
Description: MLN3126 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126
Description: MLN3126 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126
Description: MLN3126 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126
Description: MLN3126 tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN3126
Description: MLN3126 tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MLN3126 Placebo
Description: MLN3126 placebo-matching tablets
Study: NCT03219892

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-frequency rTMS
Description: It is delivered at a 5-second burst of 10Hz stimuli, repeated 20 times at every minute. Each treatment contains a total of 1000 pulses. Stimulus intensity is 90% of resting motor threshold. The SMA stimulation will be given using a coil centered at points 3-cm anterior to the leg motor area in the sagittal midline.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: The procedure will be same as the high-frequency rTMS except that the coil is 90° angled away.
Study: NCT00643357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50% Oxygen/50% Nitrous oxide premix (KALINOX 170 bar)
Description: gaz flow between 4 to 15 L/min inhalation between 15 to 60 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 50%Oxygen/50% Nitrogen premix
Description: inhalation between 15 to 60 minutes gaz flow between 4 to 15 l/min
Study: NCT04082702

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faith-enhanced diabetes prevention program
Description: The faith-enhanced curriculum was faith-based and developed using CBPR approaches. The Faith-DPP condition included delivery of the DPP. The group intervention was delivered by one to two trained peers from the church and consisted of 16 weekly group meetings followed by 6 bi-monthly or monthly maintenance sessions. The faith enhanced curriculum included five strategies: 1) a mini sermon (\~15 min in length) delivered by a pastor (head pastors were required to deliver at least one per month), first lady, or church leader (pastor associate, deacon, elder, etc.), 2) a memory verse, 3) in class or take-home faith activity (application of faith principles), 4) promises to remember, and 5) scripture and prayer integrated into participant curriculum and facilitator materials. These five faith enhancements were developed by the CAB to enhance the DPP's weekly learning objectives, which resulted in faith components specifically linked to each week of DPP content.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard diabetes prevention program
Description: The S-DPP condition was faith-placed, a secular program (the DPP) held at an faith-based organization. This condition received the same diabetes prevention program (DPP) as the Faith-DPP, but did not receive any faith enhancements or pastor involvement.
Study: NCT03061045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]
Description: All patients enrolled in this study will undergo contrast enhanced ultrasound examination for assessment of brain perfusion.
Study: NCT00546429

Intervention type: DEVICE
Intervention: Intramedullary nailing
Description: Trochanteric nailing for proximal femoral fractures.
Study: NCT02679495

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active measures of lifestyle modification
Study: NCT01089829

Intervention type: OTHER
Intervention: Foot examination
Description: Non-invasive neurological sensory testing~Non-invasive doppler assessment of peripheral arterial system

Intervention type: OTHER
Intervention: Foot examination
Description: Non-invasive neurological sensory testing~Non-invasive doppler assessment of peripheral arterial system
Study: NCT01923233

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: allogeneic Th1 memory cell with CD3/CD28-coated microbeads attached.
Study: NCT02496117

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrical mapping, nerve stimulation checked renal denervation procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrial mapping, nerve stimulation guided renal denervation procedure
Study: NCT01138865

Intervention type: DEVICE
Group type: OTHER
Intervention: AutoSet Spirit--Wash--Modified-AutoSet Spirit
Description: 3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between

Intervention type: DEVICE
Group type: OTHER
Intervention: Modified-AutoSet Spirit--Wash-AutoSet Spirit
Description: 3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
Study: NCT03962582

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Matrix back
Description: The Matrix back will replace the individual's back and the measures will be taken.
Study: NCT03075319

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Received perioperative photograph
Description: All participants in experimental group were adviced to see periopertive knee photograph before rehabilitation everyday.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups.
Study: NCT02025998

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Matched placebo
Description: A matched placebo (suggar pill) will be administered as a control condition.
Study: NCT03075319

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Didn't receive perioperative photograph
Description: All participants in active comparator group didn't receive perioperative knee photograph.~Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.~The outcome assessors were blinded to treatment groups.
Study: NCT00929331

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral®
Description: Intramuscular injection, one dose

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluviral®
Description: Intramuscular injection, one dose
Study: NCT01213693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol/Fluticasone combination
Description: Salmeterol/Fluticasone 50/500 mcg 1 inhalation bid
Study: NCT02127775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg (manufactured at Site 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg (manufactured at Site 1)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg (manufactured at Site 2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lesinurad 400 mg (manufactured at Site 2)
Study: NCT01206816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727 + BIBW 2992
Description: BI 6727 administered i.v. every 21 days + BIBW 2992 given orally once a day
Study: NCT00973765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bactrim
Description: bactrim DS (800/160) 2 pills PO BID x 7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo 2 pills po BID x 7 days
Study: NCT03947424

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LP Er:YAG
Description: LP Er:YAG applied to oral mucosa

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SMOOTH mode Er:YAG
Description: SMOOTH mode Er:YAG applied to oral mucosa

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham
Description: Er:YAG laser applied to oral mucosa with no energy
Study: NCT04243408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous umbilical cord blood transfusion
Description: single dose of an autologous umbilical cord blood transfusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The placebo product will consist of the standard ingredients of the acellular content of the UCB unit. It will consist of 20 ml Dextran (Plander 40.000 - 50g/500ml, solution for infusion) and 20 ml of human Albumin 5% (solution for infusion). The volume of placebo product will be 40 ml
Study: NCT02115217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leukotape K
Description: All interventions will be performed by a qualified physiotherapist in a standardized manner. Tape will be extended to the recommended length (120%) and applied along the outer side of the leg, along the path of the peroneal muscle. Starting in the middle of the foot arch, the tape ends 1 cm below tibial head.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham kinesiotape
Description: KT put with no effects
Study: NCT00229736

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV-hAADC-2
Description: 9 x 10\^10 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AAV-hAADC-2
Description: 3 x 10\^11 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
Study: NCT04872972

Intervention type: OTHER
Group type: OTHER
Intervention: Simulation based learning
Description: Faculty development courses on simulation based learning
Study: NCT02823483

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen Lotion (BAY987521)
Description: 50 μl/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.Formulation A: Y49-103, Formulation B: Y71-150.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated Skin
Description: This site is patched without treatment as irradiated control
Study: NCT02890836

Intervention type: DRUG
Intervention: Antihypertensiva, mainly Metyldopa
Study: NCT03537274

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-Intron
Description: PEG-Intron is administered QW for 48 weeks by SC injection at 0.5, 1.0, and 1.5 mg/kg body weight. Body weight obtained at the baseline visit is used to calculate dosing.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-Intron
Description: PEG-Intron is administered QW for 48 weeks by SC injection at 0.5, 1.0, and 1.5 mg/kg body weight. Body weight obtained at the baseline visit is used to calculate dosing.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PEG-Intron
Description: PEG-Intron is administered QW for 48 weeks by SC injection at 0.5, 1.0, and 1.5 mg/kg body weight. Body weight obtained at the baseline visit is used to calculate dosing.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Alfa-2B
Description: Interferon alfa-2b is administered TIW for 48 weeks by SC injection at 3 MIU regardless of participant body weight.
Study: NCT04430855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Tablet; Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet; Oral
Study: NCT04250948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JS001
Description: JS001, recombinant humanized anti-PD-1 monoclonal antibody for injection; 240mg ivdrip, d1, q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin: 130mg/m2，iv drip for 2h，d1, q3w
Study: NCT01213693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: Salmeterol 50 mcg 1 inhalation bid
Study: NCT02602717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lymph nodes cyto-punction
Study: NCT04250948

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1
Description: S-1: 40\~60mg Bid，d1\~14, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1
Description: S-1: 40\~60mg Bid，d1\~14, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 Bid，d1-14, q3w

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine: 1000mg/m2 Bid，d1-14, q3w
Study: NCT00430495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept was administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 21 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept was administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 21 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atacicept
Description: Atacicept was administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matched to atacicept
Description: Placebo matched to atacicept was administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
Study: NCT02122120

Intervention type: DIETARY_SUPPLEMENT
Intervention: HEN
Description: Patients with tube feeding with FSMP for at least twelve months
Study: NCT01799863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac trometamol 0.45% with carboxymethylcellulose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Preservative free artificial tear
Study: NCT01406132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP015K
Description: oral
Study: NCT02957188

Intervention type: OTHER
Intervention: 13C eicosapentaenoic acid and 13C arachidonic acid
Description: Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
Study: NCT03129464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold therapy via reusable cold gel pack
Description: Patients in the experimental group will be asked to apply cold therapy to their abdominal incisions every 6 hours for the first 72 hours following their surgery (total laparoscopic hysterectomy). Cold therapy will be applied via a reusable cold gel pack.
Study: NCT03265444

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CS10BR05
Description: The single injection of CS10BR05 Inj. in the carotid artery; Step 1 dose : 3.0x105cells/kg; Step 2 dose : 6.0x105cells/kg; Step 3 dose : 9.0x105cells/kg; The duration of follow up study following the single dose of CS10BR05 is 28 days.
Study: NCT00709436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMI-150 (intranasal ketamine)
Description: PMI-150 (intranasal ketamine) at time 0 and scheduled times thereafter.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (intranasal) at time 0 and scheduled times thereafter.
Study: NCT03593811

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patients will be provide answers to one or more of the following: Rome III criteria, BARF pictorial scale, Nausea Severity scale, Children's Somatization Inventory, State-Trait Anxiety Inventory, Functional Disability Inventory, and the Nausea Interference Scale.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 4 channel electrogastrogram (EGG)
Description: EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 4 channel electrogastrogram (EGG)
Description: EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 4 channel electrogastrogram (EGG)
Description: EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.
Study: NCT01166347

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartWare® VAS
Description: The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control LVAD
Description: Any FDA-approved LVAD for destination therapy.
Study: NCT03593811

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 4 channel electrogastrogram (EGG)
Description: EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 4 channel electrogastrogram (EGG)
Description: EGG is a non-invasive technique for recording gastric myoelectrical activity using cutaneous electrodes placed on the abdominal skin over the stomach.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 36 channel high resolution electrogastrogram (HR-EGG)
Description: HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 36 channel high resolution electrogastrogram (HR-EGG)
Description: HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 36 channel high resolution electrogastrogram (HR-EGG)
Description: HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 36 channel high resolution electrogastrogram (HR-EGG)
Description: HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 36 channel high resolution electrogastrogram (HR-EGG)
Description: HR- EGG utilizes an array of electrodes to estimate the direction and speed of gastric slow-waves using cutaneous electrodes placed on the abdominal skin over the stomach.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Magnetogastrogram (MGG)
Description: MGG measures spatiotemporal properties of magnetic fields from the gastric slow wave and allows characterization of the propagation of the gastric slow wave in addition to evaluation of its frequency and power distribution.
Study: NCT00429182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Target Area Under the Curve (AUC) of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 1.5 gm/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: 120 mg/m\^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplant
Description: Stem Cell Transplant on Day 0.